Weight loss injections are prescription medications, mainly GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide, that help adults with obesity or overweight lower their appetite and eat less. In clinical trials, paired with a reduced-calorie diet and more physical activity, these injectable medications lowered total body weight by an average of roughly 8 to 21 percent. They are FDA-approved for adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol.
What follows covers how the injections work, the three approved options, the side effects to expect, and what research shows about benefits beyond weight. Results vary from person to person, and any treatment decision should be made with a licensed healthcare provider.
Wondering whether a prescription weight loss injection is an option for you?
→ See if you qualify
A weight loss medication injection works by mimicking the natural gut hormones your body releases after you eat. These hormones, called incretins, tell your brain that you are full and help regulate blood sugar. The injectable versions are long-acting, so the fullness signal lasts much longer than it would after a normal meal.
GLP-1 receptor agonists such as liraglutide and semaglutide act on GLP-1 receptors in the brain's appetite and reward centers. This promotes a feeling of fullness and reduces food intake. They also slow how quickly the stomach empties, which helps you feel satisfied for longer and take in fewer calories.
Tirzepatide works on two pathways instead of one. As a dual agonist, it activates both the GIP and the GLP-1 receptors. Hitting two hormone pathways at once appears to add to the effect on appetite and metabolic regulation, which is part of why tirzepatide tends to produce the largest average weight loss of the three.
Beyond appetite, these medications improve insulin sensitivity and reduce glucagon secretion, and research has linked them to anti-inflammatory and heart-protective effects, including improvements in blood pressure, lipids, and C-reactive protein. Because they act on appetite and metabolism rather than burning fat directly, they work best alongside changes to diet and activity, not in place of them.
Three injectable medications for weight loss are currently FDA-approved as long-term treatments for weight management. All are given as a small injection under the skin, usually in the abdomen, thigh, or upper arm, and all start at a low dose that is increased gradually to reduce side effects.
| Medication | Type | Typical dosing | Average weight loss vs. placebo (clinical trials) |
| Liraglutide (Saxenda) | GLP-1 receptor agonist | 0.6 mg under the skin daily, titrated weekly to 3.0 mg | About 5 to 6% |
| Semaglutide (Wegovy) | GLP-1 receptor agonist | 0.25 mg weekly, titrated every 4 weeks to 2.4 mg | About 11 to 12% |
| Tirzepatide (Zepbound) | Dual GIP/GLP-1 receptor agonist | 2.5 mg weekly, titrated every 4 weeks to 5 to 15 mg | About 12 to 18% |
The differences in effectiveness are meaningful. Semaglutide is substantially more effective than liraglutide: in head-to-head data, more than 70 percent of patients lost at least 10 percent of their starting weight with semaglutide, compared with fewer than 26 percent with liraglutide. Tirzepatide at the 15 mg dose achieved the greatest weight loss in trials, with about 91 percent of patients losing at least 5 percent and 84 percent losing at least 10 percent of body weight. These are trial averages, and your own response may be higher or lower.
A couple of clarifications. These are not the older off-label or compounded products sometimes sold online, and they do not replace the everyday habits that support a healthy weight. The FDA approved them for use with a reduced-calorie diet and increased physical activity, so the medication does part of the work by making appetite easier to manage while you build eating and movement habits you can keep. Cost, insurance coverage, and supply can also vary by medication and pharmacy, which is another reason a provider-guided plan helps you pick an option you can realistically stay on. A telehealth evaluation is one way to review these factors without an in-person visit.
Not sure which option fits your health history? A licensed provider can help you decide.
→ Take the 2-minute eligibility quiz
These injections have been studied in large clinical trials and are considered safe for appropriate candidates under medical supervision, but they do carry side effects. The most common are gastrointestinal and usually ease over time, especially when the dose is increased slowly.
The profile differs slightly between medications. Pharmacovigilance data suggest tirzepatide has the highest relative risk of vomiting and gastroenteritis, semaglutide has the highest risk of abdominal pain and gallstones, and liraglutide has the highest risk of diarrhea and indigestion.
Less common but important risks to discuss with your provider include:
All three medications carry a boxed warning about thyroid C-cell tumors, based on rodent studies. They are not recommended for people with a personal or family history of medullary thyroid carcinoma or the genetic condition MEN2. Providers continue to draw on comparative pharmacovigilance data across liraglutide, semaglutide, and tirzepatide to match a medication to each patient. This is why a full medical history review matters before you start, and why these medications are prescription-only. Talk to a healthcare provider about your personal risk factors.
Research increasingly shows that GLP-1 injections can help your health beyond weight loss itself. The strongest evidence so far comes from cardiovascular outcomes trials.
The SELECT trial, which followed 17,604 participants, found that weekly semaglutide 2.4 mg reduced the combined risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke by 20 percent in people with established cardiovascular disease and overweight or obesity who did not have diabetes. The benefit appeared to extend beyond the weight loss, with only about a third of the risk reduction explained by changes in waist circumference.
Reporting in the New England Journal of Medicine (2023), A. Michael Lincoff, MD, and colleagues noted that the gap in cardiovascular events between the groups showed up early in the trial. They suggested that physiological changes happening faster than, and separate from, the amount of weight lost may have driven at least part of the heart benefit. That points to effects on inflammation, blood vessels, and metabolism rather than weight alone. These results apply to a specific high-risk group and do not mean everyone will see the same cardiovascular outcome.
Obesity is a chronic condition, and stopping these medications usually leads to substantial weight regain. The STEP-1 extension study found that patients regained roughly two-thirds of the weight they had lost within a year of stopping semaglutide, with a parallel decline in measures such as blood pressure and cholesterol.
Meta-analyses report an average regain of about 5.6 to 9.7 kg after stopping GLP-1 receptor agonists, with more rebound over longer follow-up and with semaglutide compared with liraglutide. For this reason, the American Diabetes Association Standards of Care recommend that weight management medication generally be continued long term to sustain the benefits, with shared decision-making between patient and provider about the right maintenance plan. For most people these are long-term medications rather than a short course, which is worth weighing before you begin.
Ready to talk through whether long-term treatment makes sense for you?
→ Take the 2-minute eligibility quiz
Who qualifies for weight loss injections?
FDA labeling covers adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. A provider also reviews your medical history, current medications, and any contraindications before prescribing. The fastest way to find out is to complete a short eligibility quiz.
What is the most effective weight loss injection?
In clinical trials, tirzepatide at higher doses produced the largest average weight loss, followed by semaglutide, then liraglutide. The best choice for any individual depends on health history, insurance coverage, and how the body responds, which is a conversation to have with a licensed provider.
How quickly do weight loss injections start working?
Appetite changes often begin within the first few weeks, but doses are raised gradually over a couple of months to limit side effects, so the fuller effect builds over time. Results vary from person to person.
How long do you need to stay on weight loss injections?
Because weight tends to return after stopping, current guidelines treat these as long-term medications for most patients. Your provider will help you settle on a maintenance approach that fits your goals and health.
Do weight loss injections have serious risks?
Most side effects are gastrointestinal and tend to ease over time. Less common risks include gallbladder disease and injection site reactions, and there is a boxed warning regarding thyroid C-cell tumors. People with a personal or family history of medullary thyroid carcinoma or MEN2 should not use these medications. Always review your full history with a healthcare provider.
See whether a prescription weight loss injection could be right for you. It takes about two minutes.
→ Check your eligibility
Learn more: FDD Weight Loss Program | Eligibility quiz
